Source：The Insides Company Limited
On：1st Sep 2026
Organisation：The Insides Company Limited
The French National Authority for Health issues a favourable opinion for the inclusion of The Insides System on the List of Reimbursable Products and Services (LPPR), marking a decisive step towards long-term reimbursement for patients with type II intestinal failure.
Auckland (New Zealand) and Paris (France), 1 September 2026 – The Insides Company¹, a New Zealand medtech company specialising in the development of innovative devices for the treatment of intestinal failure, today announces that the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS) of the French National Authority for Health (HAS) has issued a favourable opinion for the inclusion of The Insides System® on the List of Reimbursable Products and Services² (LPPR).
The Commission determined that The Insides System provides a sufficient Expected Benefit (SA) as well as a Level IV Improvement in Expected Benefit (ASA) for the treatment of intestinal failure associated with a temporary double enterostomy or a high-output enterocutaneous fistula, through the active reinfusion of chyme³ into the distal intestine.
This favourable opinion for inclusion on the LPPR marks a major milestone in the pathway towards reimbursement of this innovative technology in France. It follows the favourable opinion issued by HAS in July 2022 and the granting of Transitional Coverage (PECT) in 2023. Effective inclusion on the LPPR will take place following completion of the next regulatory steps.
“We are delighted with the favourable opinion issued by the French National Authority for Health, which represents a major step towards broader access to The Insides System® for patients in France. This decision is part of France’s longstanding tradition of excellence in research and clinical practice in medical nutrition, which has helped establish France as an international leader in this field. We would also like to warmly thank all healthcare professionals from the accredited Home Parenteral Nutrition Centres (NPAD), as well as the patients whose trust and commitment have contributed for many years to advancing this therapeutic approach,” explains Garth Sutherland, CEO of The Insides Company.
“Active and intermittent chyme reinfusion is an innovative approach that addresses an important medical need in particularly vulnerable patients. This favourable opinion represents a significant step towards broader access to this technology, for the benefit of both patients and healthcare teams,” adds Professor Didier Quilliot, coordinator of the expert nutrition centre at Nancy University Hospital and President of the French-speaking Society for Clinical Nutrition and Metabolism⁴ (SFNCM).
An innovation designed to restore the physiological continuity of the intestine
In patients with a temporary double enterostomy or a high-output enterocutaneous fistula, a significant proportion of nutrients, water, electrolytes and digestive secretions is discharged before it can be absorbed by the intestine. As a result, the body no longer receives sufficient nutrients and fluids to meet its needs, often requiring parenteral nutrition, meaning nutrients are delivered directly into the bloodstream intravenously.
This treatment is essential but may be required for an extended period and can expose patients to complications, particularly those associated with venous catheters, as well as deterioration in their quality of life.
The Insides System collects the chyme discharged through the stoma and reinfuses it into the distal part of the intestine. By restoring the passage of digestive contents through the portion of the intestine that was no longer being used, the device restores the natural mechanisms for absorbing water, nutrients and electrolytes.
The intestine can therefore progressively regain its digestive function, which may reduce the need for parenteral nutrition in some patients and, in some cases, enable it to be discontinued entirely.
Data from the REINFUSE study, the first randomised controlled clinical trial evaluating chyme reinfusion assisted by The Insides System® in patients with type II intestinal failure, supported the clinical submission reviewed by the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS) within the French National Authority for Health (HAS).
The full results of this study will shortly be published in an international peer-reviewed journal.
About The Insides Company
The Insides Company is a New Zealand medical technology company specialising in the development of innovative devices for the treatment of intestinal failure.
Its device, The Insides System, enables active chyme reinfusion in order to restore functional intestinal continuity, reduce reliance on parenteral nutrition and improve patient care.
The company draws on more than thirty years of clinical expertise in the field of chyme reinfusion.
About The Insides System
The Insides System is a medical device intended for the treatment of intestinal failure associated with a temporary double enterostomy or a high-output enterocutaneous fistula.
It collects chyme discharged through a stoma and reinfuses it into the distal intestine in order to restore the physiological functioning of the digestive tract and support patient recovery.
Press contact：
Florence Portejoie
FP2COM Agency
fportejoie@fp2com.fr
06 07 76 82 83
¹ https://www.theinsides.co
² https://www.has-sante.fr/upload/docs/evamed/CNEDIMTS8146_THE%20INSIDES%20SYSTEM_23%20juin%202026_8146_avis.pdf
³ Chyme is the semi-liquid mixture of partially digested food that travels through the intestine and enables the absorption of nutrients. In some patients with intestinal failure, this chyme can no longer follow its natural pathway, resulting in a significant loss of nutrients. The Insides System enables this chyme to be reintroduced in order to restore its digestive pathway and promote improved nutrient absorption.
⁴ https://www.sfncm.org
Read more：
The Insides Company franchit une nouvelle étape vers le
© 2026 The Insides Company. All copyright, design, patent and intellectual property rights existing in our designs and products and in the images, text and design of our website / marketing material are the property of The Insides Company.
.png){kind=small}
.png){kind=small}
